Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Chronic Hepatitis B

In brief

This Phase 1b trial will assess the dose-related safety and PK profile of different doses of NVR 3-778 in patients with chronic hepatitis B. Additionally,changes in patients' serum HBV DNA levels and other virologic efficacy parameters will be assessed.

Key facts

Study ID

NCT02401737

Run by

Novira Therapeutics, Inc.

People needed

58

Starts

2015-01-31

Expected to finish

2016-05-18

Last updated by the study team

2017-10-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Costa Mesa, California, United States
• Study site — Pasadena, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — Hong Kong, China
• Study site — Singapore, Singapore
• Study site — Chuncheon, South Korea
• Study site — Seongnam, South Korea
• Study site — Kaohsiung City, Taiwan
• Study site — Keelung, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.